- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Activist hedge fund seeks big shake-up at Novavax | ||
| Mo | Regeneron launches $500m venture capital arm | ||
| Mo | Healthware re-launches as Eversana Intouch full service affiliate | ||
| Mo | Study warns of chronic kidney disease timebomb | ||
| Mo | After ph3 win, Roche eyes earlier use of Columvi in DLBCL | ||
| Mo | EMA finds no suicide risk with GLP-1 diabetes, obesity drugs | ||
| Fr | BioMarin's Voxzogo shows promise in hypochondroplasia | ||
| Fr | TORL rakes in $158m for ADCs, and other bio financings | ||
| Fr | AZ shareholders back CEO Soriot's pay package, amid dissent | ||
| Fr | Ex-broadcaster Paxman hands Parkinson's wish list to UK PM | ||
| Fr | Novartis adds clinical-stage protein degrader from Arvinas | ||
| Do | NICE backs AbbVie's oral therapy for migraine prevention | ||
| Do | US accuses Regeneron of fraud in Eylea price reporting | ||
| Do | FDA puts breakthrough tag on Roche, Lilly Alzheimer's test | ||
| Do | EU pharma reform package clears key Parliament vote | ||
| Do | Vertex wagers $4.9bn on Alpine Immune kidney disease therapy | ||
| Mi | Roche gets EU okay for first HER2-low test kit | ||
| Mi | e-therapeutics is latest UK biotech to seek AIM de-listing | ||
| Mi | UK calls time-out on post-Brexit rules opposed by industry | ||
| Mi | Essential adds neuroblastoma drug with Renaissance buy | ||
| Mi | Bayer, Google partner on AI for time-pressed radiologists | ||
| 09.04. | Ubie AI aims to improve diagnosis of rare disease Cushing's | ||
| 09.04. | UK survey finds deep ethnic divisions in cancer diagnosis | ||
| 09.04. | NHS trust bids to take license for abandoned gene therapy | ||
| 09.04. | Ex-Karuna team launch Seaport with $100m for psychiatry meds |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
